Logo image of ANNX

ANNEXON INC (ANNX) Stock Fundamental Analysis

USA - NASDAQ:ANNX - US03589W1027 - Common Stock

3.16 USD
+0.01 (+0.32%)
Last: 10/20/2025, 7:32:30 PM
3.16 USD
0 (0%)
After Hours: 10/20/2025, 7:32:30 PM
Fundamental Rating

2

Taking everything into account, ANNX scores 2 out of 10 in our fundamental rating. ANNX was compared to 534 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for ANNX as it has an excellent financial health rating, but there are worries on the profitability. ANNX does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ANNX has reported negative net income.
ANNX had a negative operating cash flow in the past year.
In the past 5 years ANNX always reported negative net income.
ANNX had a negative operating cash flow in each of the past 5 years.
ANNX Yearly Net Income VS EBIT VS OCF VS FCFANNX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

The Return On Assets of ANNX (-71.35%) is worse than 62.17% of its industry peers.
The Return On Equity of ANNX (-94.86%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -71.35%
ROE -94.86%
ROIC N/A
ROA(3y)-44.79%
ROA(5y)-39.91%
ROE(3y)-54.04%
ROE(5y)-47.75%
ROIC(3y)N/A
ROIC(5y)N/A
ANNX Yearly ROA, ROE, ROICANNX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ANNX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ANNX Yearly Profit, Operating, Gross MarginsANNX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

7

2. Health

2.1 Basic Checks

The number of shares outstanding for ANNX has been increased compared to 1 year ago.
ANNX has less shares outstanding than it did 5 years ago.
ANNX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ANNX Yearly Shares OutstandingANNX Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
ANNX Yearly Total Debt VS Total AssetsANNX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -2.79, we must say that ANNX is in the distress zone and has some risk of bankruptcy.
ANNX's Altman-Z score of -2.79 is in line compared to the rest of the industry. ANNX outperforms 46.63% of its industry peers.
There is no outstanding debt for ANNX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.79
ROIC/WACCN/A
WACCN/A
ANNX Yearly LT Debt VS Equity VS FCFANNX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M 300M

2.3 Liquidity

ANNX has a Current Ratio of 5.67. This indicates that ANNX is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of ANNX (5.67) is better than 61.05% of its industry peers.
ANNX has a Quick Ratio of 5.67. This indicates that ANNX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 5.67, ANNX is in the better half of the industry, outperforming 61.24% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.67
Quick Ratio 5.67
ANNX Yearly Current Assets VS Current LiabilitesANNX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for ANNX have decreased by -4.88% in the last year.
EPS 1Y (TTM)-4.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-47.83%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 31.72% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-37.23%
EPS Next 2Y-14.52%
EPS Next 3Y5.55%
EPS Next 5Y31.72%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ANNX Yearly Revenue VS EstimatesANNX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
ANNX Yearly EPS VS EstimatesANNX Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ANNX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ANNX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ANNX Price Earnings VS Forward Price EarningsANNX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ANNX Per share dataANNX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-14.52%
EPS Next 3Y5.55%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ANNX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ANNEXON INC

NASDAQ:ANNX (10/20/2025, 7:32:30 PM)

After market: 3.16 0 (0%)

3.16

+0.01 (+0.32%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-14 2025-08-14/amc
Earnings (Next)11-12 2025-11-12
Inst Owners93.23%
Inst Owner Change0.02%
Ins Owners0.57%
Ins Owner Change2.15%
Market Cap347.25M
Analysts84.29
Price Target11.83 (274.37%)
Short Float %9.4%
Short Ratio5.79
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-6.77%
Min EPS beat(2)-22.39%
Max EPS beat(2)8.85%
EPS beat(4)2
Avg EPS beat(4)-7.11%
Min EPS beat(4)-22.39%
Max EPS beat(4)8.85%
EPS beat(8)6
Avg EPS beat(8)5.97%
EPS beat(12)10
Avg EPS beat(12)9.8%
EPS beat(16)11
Avg EPS beat(16)7.49%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)4.03%
EPS NY rev (1m)1.01%
EPS NY rev (3m)5.54%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.74
P/tB 1.74
EV/EBITDA N/A
EPS(TTM)-1.29
EYN/A
EPS(NY)-1.34
Fwd EYN/A
FCF(TTM)-1.42
FCFYN/A
OCF(TTM)-1.42
OCFYN/A
SpS0
BVpS1.81
TBVpS1.81
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -71.35%
ROE -94.86%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-44.79%
ROA(5y)-39.91%
ROE(3y)-54.04%
ROE(5y)-47.75%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 4.83%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.67
Quick Ratio 5.67
Altman-Z -2.79
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)106.39%
Cap/Depr(5y)92.98%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-4.88%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-47.83%
EPS Next Y-37.23%
EPS Next 2Y-14.52%
EPS Next 3Y5.55%
EPS Next 5Y31.72%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-58.38%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-53.54%
EBIT Next 3Y-8.46%
EBIT Next 5YN/A
FCF growth 1Y-22.22%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-22.74%
OCF growth 3YN/A
OCF growth 5YN/A